Latest Intelligence on Drug Delivery in United States

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Cipro sales under threat, while generics expand market

Recent events threaten to further erode US sales of Bayer's Cipro franchise as the pharma battles against greater generic competition and limited uptake of follow-up product Cipro XR. As Datamonitor's Amber Gibson explains, novel generic formulations could potentially find opportunities for greater market diversity, even though this may not be associated with increased value...

Published By Datamonitor
07 Jul 2004
CommentWire
CommentWire

Chiron: sniff competition

Chiron and West Pharmaceutical Services have agreed to develop and market a diphtheria and tetanus nasal vaccine using West Pharmaceutical's ChiSys nasal drug delivery technology. The combination would be most relevant for adult booster vaccinations - a market where the needleless delivery method is likely to be well appreciated by both patients and physicians.

Published By Datamonitor
25 Mar 2003
CommentWire
CommentWire

Chiron: inhaled immunosuppressant offers transplant hope

The results of a new study show that lung transplant recipients have a lower risk of death following transplant surgery if they use a new inhaled form of the immunosuppressant cyclosporine. Chiron [CHIR] is developing the inhaled drug to capture a share of the valuable transplant patient market, and the novel delivery system may yet find wider application.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Cell Therapeutics: Xyotax faces more developmental delays

On the recommendation of the Data Safety Monitoring Board, Cell Therapeutics has suspended enrollment in testing Xyotax for pre-menopausal, poor performance status (PS2), female advanced non-small cell lung cancer (NSCLC). As Xyotax is targeting such a specific patient cohort, this six-month delay could prove costly, with Cell Therapeutics now heavily relying upon the drug's FDA Fast Track status.

Published By Datamonitor
07 Nov 2006
CommentWire
CommentWire

Cell Therapeutics: a taxing time for Xyotax?

Clinical trials have, so far, shown that Cell Therapeutics' Xyotax may improve lung cancer treatment by reducing chemotherapy side effects and requiring less infusion time. However, the lung cancer market is likely to be crowded with generic and reformulated paclitaxel in the coming years and Cell Therapeutics will need to team up with a larger pharmaceutical company to market Xyotax effectively.

Published By Datamonitor
29 Apr 2003
Expert View
Expert View

Cancer: the generic impact

The cancer market is set for a boom in low cost drugs, as a significant number of high value cancer drugs are set to lose patent protection over the next decade, triggering a dramatic influx of cheaper generic equivalents. But as patients and generics manufacturers bask in the glow, pharmaceutical companies will be forced to gamble on innovation for fear of being left out in the cold?<BR />

Published By Datamonitor
20 Sep 2002
CommentWire
CommentWire

Cancer pain: education is the key

The high level of under-treatment for cancer pain is a result of poor diagnosis, assessment, and treatment by physicians. It is coupled with an unfounded fear of the use of controlled drugs such as opioids. The key to better management of cancer pain is improved educational programs and the development of dedicated pain management teams.<BR />

Published By Datamonitor
27 Mar 2003
CommentWire
CommentWire

Bristol-Myers Squibb/Sanofi-Aventis: Plavix deal under threat

Bristol-Myers Squibb and Sanofi-Aventis' proposed settlement with generics firm Apotex, designed to end the companies' dispute over Plavix' US patent protection, has been called into question. It appears the deal could contravene an agreement BMS made with US regulators in 2003. Investors will be worried that, if the pact collapses, conflict over the blockbuster drug's key patent could resurface.

Published By Datamonitor
12 Jul 2006
Expert View
Expert View

Bristol-Myers damp squib

After a spate of set backs Bristol-Myers Squibb has been forced to make a profit warning. While generic competition has eaten away at sales, the company's pipeline has failed to produce drugs capable of bolstering the waning revenues. So, with no signs of a reprieve, will Bristol-Myers be able to fight off unwelcome suitors or is a take-over in the offing?

Published By Datamonitor
26 Apr 2002
CommentWire
CommentWire

BMS: paying the price of Q4 push

More bad news for BMS: US sales are down from $2.7 billion in Q2 2001 to $1.8 billion last quarter. The massive sales push that inflated wholesalers' stocks in Q4 2001 has hit 2002 sales hard; so has generic competition for three key drugs. The most serious concern at this time is whether there is any source for a sales recovery.

Published By Datamonitor
25 Jul 2002

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

No help is available.